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A B S T R A C T
Introduction. The high effectiveness of phosphodiesterase type 5 inhibitors (PDE5-i) in the treatment of erectile
dysfunction (ED) has been demonstrated. However, previous research shows that PDE5-i treatments have high
discontinuation rates.
Aim. The main goals of this study were to (i) characterize the way men use PDE5-i and (ii) analyze the adherence
to treatment, identifying the factors that inﬂuence PDE5-i use.
Methods. A total of 148 men with clinical diagnosis for ED who maintained the treatment with PDE5-i for over 3
years were interviewed. Interviews concerning their ongoing treatment were carried out using a standardized
questionnaire with quantitative and qualitative items.
Main Outcome Measures. Physiological measures included the intracavernous alprostadil injection test, associated
with penile rigidometry and penile Doppler ultrasound. The qualitative measure included two questions: “Do you
use the drug in every sexual intercourse?” and “How do you use the inhibitor?”
Results. ED causes were classiﬁed as venogenic (31%), arteriogenic (23%), psychogenic (18%), iatrogenic (13%),
neurogenic (8%), and diabetic (7%). Participation rate was 71.8%. Of the 148 patients studied, 75% claimed not to
use PDE5-i in every intercourse. Most used tadalaﬁl (66%), followed by sildenaﬁl (20%), vardenaﬁl (10%), and 4%
alternated the type of medicine. Four main categories emerged concerning the factors that determine the intake of
PDE5-i in some intercourse situations and not in others: (i) psychological factors; (ii) medication-related factors; (iii)
circumstantial factors; and (iv) relational factors.
Conclusion. The analysis of men’s narratives revealed a combination of factors that inﬂuence the adherence to
PDE5-i. The psychological and medication-related factors were the most prevalent. This study highlighted the
importance of taking these factors into account, both at the time of prescription and during the follow-up in order
to improve adherence. Carvalheira A, Forjaz V, and Pereira NM. Adherence to phosphodiesterase type 5
inhibitors in the treatment of erectile dysfunction in long-term users: How do men use the inhibitors? Sex
Med 2014;2:96–102.
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Introduction
The oral agents for treatment of erectile dys-function (ED) belonging to the group of
phosphodiesterase type-5 inhibitors (PDE5-is) are
described in the literature as effective, safe, and
easy to administer [1–4]. However, their use is
often described by clinicians as involving a pattern
of repeated medication intake, often followed by
abandonment of the treatment, even when it is
effective [5]. These data suggest that the improve-
ment of erectile function is not the only, or even
the most important, factor involved in the success
of the treatment [6].
Research reveals high discontinuation rates
[7–14], suggesting that some of these men may
have characteristics speciﬁc to their sexual attitude
and perception of sexual relationships [6]. A recent
study [13] with a sample of 327 men with ED who
undertook PDE5-i revealed a discontinuation rate
of 48.9%. A qualitative analysis of the reasons for
dropout revealed as main reasons the insufﬁcient
effectiveness of PDE5-i (36.8%) and psychological
factors (e.g., anxiety, negative emotions, fears, con-
cerns, dysfunctional beliefs). It is also known that
treatment with PDE5-i among men may follow
very irregular patterns [15]. Several studies have
attempted to clarify the process of adherence to
treatment [5,16–18]. In a qualitative study with 33
men and 27 women [16] evaluating the impact of
sildenaﬁl use, the results demonstrated that some
participants used a dose lower than prescribed or
used the medication intermittently.
Some studies have also shown that a signiﬁcant
percentage of men alternate between several avail-
able drugs [19,20]. The spontaneity and natural-
ness of sexual intercourse, the acceptance of the
treatment by the partner, and the speed/duration
of the action seem to be decisive in the choice of
medication [21]. Variables such as the cost and
rationing of medication have also been described
as inﬂuential in treatment adherence, especially in
patients with lower incomes [18,21]. However,
these different studies do not address systemati-
cally the patients’ adherence to PDE5-i and are
not consensual regarding the reasons that may
inﬂuence the medication intake in men.
Aim
Two main research questions emerged: “Which
factors are responsible for patients’ adherence to
PDE5-i?” and “How do patients use these drugs?”
We sought to (i) characterize the way men use
PDE5-i (inhibitor type, frequency of use, side
effects) and (ii) analyze the adherence to treatment,
identifying the factors that inﬂuence PDE5-i use.
Method
Participants
The study sample consisted of 148 adult male
patients at an andrological outpatient’s clinic, aged
25–81 years, with clinical diagnosis of ED who
initiated and maintained the treatment with
PDE5-i for over 3 years, in a regular basis of at least
every 3 months. Exclusion criteria included: taking
antidepressants, history of alcohol and substance
abuse, hypogonadism, Peyronie’s disease, and pres-
ence of a severe psychopathological disorder.
Although these exclusion criteria would be
interesting to include in the sample, they could
also contribute to hide the main reasons why
patients are not adhering to PDE5-i treatment.
Also, antidepressants intake could interfere with
sexual desire and arousal, which ultimately could
lead the results into inaccurate analysis.
Instrument
A comprehensive, detailed questionnaire was
developed and piloted for this study, based on the
literature review and on the researcher’s clinical
experience. This was a 29-item questionnaire (see
Appendix), which included quantitative and quali-
tative variables (incorporating sociodemographic,
clinical, and adherence-related items).Quantitative
variables include demographics, type of PDE5-i
and frequency of use, other previous treatments,
side effects, expectations regarding the treatment,
and partner involvement. Regarding qualitative
variables, men were asked if they used the PDE5-i
in every intercourse. When the answer was “No”,
an open-ended question was presented: “How do
you take the inhibitor?” When the participants’
answers were not clear, the question was reformu-
lated: “Why don’t you take the PDE5-i in every
single sexual intercourse?”
We chose a phenomenological approach, given
our interest in the meanings given by individual
men regarding this phenomenon [22].
Procedure
Patients were contacted by telephone and, after
their authorization, they received an informed
consent by mail at the discharge address; at this
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point, full written information about the project
and its aims were provided. Subjects were con-
tacted for a second time after 1 week. Once con-
ﬁrmation had been received from the potential
participants, a telephone interview was scheduled.
Interviews lasted between 30 and 50 minutes. A
neutral research assistant conducted interviews
using the standardized questionnaire form in a
Google Docs online research database. Complete
qualitative and quantitative data from the inter-
views were introduced directly through the live
form and stored in the study database. This
study received ethical approval from the Ethics
Committees of ISPA-University Institute and
Lusófona University.
Results
Study Population
A total 148 men were interviewed (participation
rate = 71.8%). The average age of participants was
55.8 years (standard deviation 11.11, range 25–81).
Most were in a committed relationship (87.8%)
and reported heterosexual behavior (98%). A total
of 22.9% were smokers. Data on educational level,
religion, marital status, and relationship status are
summarized in Table 1.
Characterization of the Use of PDE5-i
Of the 148 patients studied, the vast majority of
participants (75.2%) claimed not to use the
PDE5-i in every intercourse. Most used tadalaﬁl
(65.8%), followed by sildenaﬁl (19.9%) and
vardenaﬁl (10.3%). The remaining patients alter-
nated the type of drug (42%).
The daily use of a PDE5-i was only for tadalaﬁl
5 mg, which was used by 9.1% of total patients.
Most men used the drug once or twice a week
(42%), followed by patients who used the inhibitor
once or twice per month (25.2%), and those using
less than once per month (23.7%).
Of the total respondents, 51.2% tried at least
one other treatment, before or during the use of
PDE5-i, particularly other oral agents (e.g.,
nicergoline, yohimbine) intracavernous injections,
natural products, and sex therapy. However, this
did not lead to the abandonment of PDE5-i.
Of the respondents, 54.5% reported side
effects (e.g., dyspepsia, nasal congestion, and
headaches) but always with mild intensity, so
there were no cases of deﬁnitive discontinuation
of therapy.
Despite maintaining therapy, 19.3% of patients
considered that the results of PDE5-i treatment
did not meet their needs and expectations.
The Partner of Patients Taking PDE5-i
Of the 148 men in the sample, 42.5% described
their partner as “sexually active,” 35% answered
“more or less sexually active,” and 22.5% reported
the partner as “a little” or “not sexually active.” A
total of 27.9% of men considered that their
partner was not important in solving the problem,
and 18.8% of men reported that their partner was
unaware that they were taking a PDE5-i. Only
18.5% of men had attended the ﬁrst consultation
with their partner.
Adherence to PDE5-i: Factors Influencing Use
The analysis of the factors reported by the 148
patients was made from the responses to the fol-
lowing two questions: “Do you use the drug in
every sexual intercourse?” and “How do you use
the inhibitor?” Based on the content analysis per-
formed, the responses were organized into four
main categories: (i) psychological factors; (ii)
factors associated with the drug; (iii) circumstantial
factors; and (iv) relational factors.
Table 2 characterizes these categories, each
divided into factors, which were frequently
detected as weighing on the patient’s decision to
use or abstain from the drug.
Psychological Factors
Despite taking medication consistently for over 3
years, 44% of respondents reported psychological
factors inﬂuencing their intake patterns.
Table 1 Participants’ characteristics
Educational level
Undergraduate 58.1%
Graduate 33.8%
Postgraduate 8.1%
Religion
Catholic (observant) 58.1%
Catholic (practicing) 19.6%
Other religion (practicing) 1.4%
No religion 20.9%
Marital status
Married 61.5%
Divorced/separated 20.3%
Single 12.2%
Common law 4.1%
Widowed 2.0%
Relationship status
In a committed relationship 87.8%
Occasional partner 6.1%
Regular sexual partner 3.4%
Without sexual partner 2.7%
Mean age 55.8 (standard deviation 11.11, range 25–81)
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Other men (n = 15) reported taking the inhibi-
tor to guarantee they would not to fail sexually:
I’m a bit young. This gets into a man’s head . . . think-
ing “I will falter”, then it really falters. The Cialis
helps—it was good for the head. I no longer think much
about it. (33 years old, divorced, has casual partners)
Sometimes (n = 12), the intake of the inhibitor was
dependent on negative emotional states:
It depends on the emotional state. Sometimes my head
is free from hassles and problems and things just
happen. When a person has his head full, we notice it
for sure. When I feel that I am like that, I take half a
tablet. (50 years old)
Some qualitative accounts translated fear in rela-
tion to the medication, although patients have
never felt any signiﬁcant side effects. Eight men
reported fear of side effects, which they could not
deﬁne, and six showed concern about the cardio-
vascular safety of the drug. Seven patients justiﬁed
their intermittent intake with the fact that they
avoid taking any type of medication, including
PDE5-i.
The average age of the men, in whose narratives
we detected psychological factors, was 50 years,
ranging between 30 and 81 years.
Factors Associated with the Medication
These factors include a set of patients (n = 30) who
stated not taking PDE5-i in every intercourse.
Eight patients stated that the price of the drug
prevented them from taking the inhibitor more
frequently:
I do not take [it] more often because they are expensive.
I buy the 20 mg and cut [them] in half. As sexual activity
is not much, the 8 bits are enough for two months. (64
years old)
The presence of side effects as a barrier was
reported by seven men, which implied that they
would only take the drug in an intermittent and
infrequent manner. The average age of men who
pointed out factors associated with the drug was 65
years old, ranging between ages 40 and 78.
Relationship Factors
In this category, we ﬁnd the patients (n = 35) who
stated that taking the PDE5-i is mediated or hin-
dered by relational factors.
The exclusive use of a PDE5-i in extramarital
affairs was reported by 13 participants:
I cannot have erections outside of matrimony. I have a
regular sex life within the marriage. Outside of matri-
mony I could not, and resorted to the doctor. (48 years
old, taking tadalaﬁl 20 mg for 5 years, less than once a
month)
Nine patients were dependent on sexual activity
and the physical and emotional stimulation by
their partner:
It is not necessary to use it more often because I adjust
my doses according to my wife’s needs. I take the pills
according to my wife’s psychological and physical avail-
ability to have sex. (64 years old)
Five patients reported the lack of communication
or conﬂict with their partner disturbed the use of
the PDE5-i:
I do not take it all of the time because there is little
dialogue between the couple, about the best and worst
days, about all that . . . it is because of the lack of
dialogue. And there is a certain complacency. (55 years
old, intermittently taking tadalaﬁl 10 mg for around
6 years)
Five patients stated that their partners did not
always accept the inhibitor. The average age of the
Table 2 Factors determining the intake of PDE5-i intake
in some intercourse situations and not in others (N = 148)
Psychological
factors
Self-confidence 11.4%
To avoid a bad performance 10.1%
Psychological and emotional state 8.1%
Fear of the side effects 5.4%
Be averse to taking medication 4.7%
Fear that it is harmful for the heart 4.0%
Total 44.0%
Medication-
related factors
Efficacy not complete (organicity) 15.5%
High price 5.4%
Prolonged effect 4.7%
Side effects 4.7%
Total 30.3%
Relational
factors
Extramarital relations 8.7%
Lack of emotional and physical
stimulus by the partner
6.0%
Lack of communication and
conflicts
3.3%
Partner’s difficulty in accepting
PDE5-i use
3.3%
Not having sexual intercourse or
stable partner
2.0%
Total 23.6%
Circumstantial
factors
To improve performance 6.7%
Difficulty in programming the
inhibitor intake and geographical
distance from the partner
8.7%
Alternating between different
PDE5-i
2.7%
Alternating between PDE5-i and a
natural product or another drug
2.0%
Forgetting to buy or to get medical
prescription
2.0%
Total 22.2%
PDE5-i = phosphodiesterase type-5 inhibitor
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men who indicated relational factors was 54, with
ages ranging between 33 and 66 years old.
Circumstantial Factors
The circumstantial factors reported by 33 patients
included situations where the intake of PDE5-i
was mediated by a punctual situation, not very
stable in time, whether it was recurrent or not.
Ten men claimed taking the inhibitor only in
special moments to prolong the pleasure or to
improve their performance:
When there is more availability and we want things to
last longer, we use it—on a weekend, when the kids are
at their grandparents, or when there is another available
moment for each other. (42 years old)
The difﬁculty in scheduling the medication intake
was another situation reported by nine men:
In the sexuality things, we do not choose a day or an
hour. Generally, there is a certain impossibility of
programming—the situation arises by itself and some-
times it would make sense to have taken [it] and other
times reveals not to have been necessary. (53 years old)
Four men stated that they switch between the dif-
ferent PDE5-is according to the circumstances
and objectives. Moreover, three participants said
they alternate the inhibitor with certain foods or
other natural products purchased at the pharmacy.
The average age of the men who indicated cir-
cumstantial factors was 54 years, ranging between
33 and 71 years of age.
Discussion
The aim of this study was to analyze the factors
inﬂuencing patients’ adherence to, and use of,
PDE5-i in a sample of 148 patients who used the
inhibitor for a 3-year period.
The results showed that although most men do
not take the medication in every intercourse, most
use it one to two times a week, similar to the
ﬁndings of other comparable studies [5,16–18].
The fact that most men used tadalaﬁl (65.8%)
can suggest that the duration of the drug’s action
and preserving the spontaneity are important
factors in the choice of an inhibitor. Only a minor-
ity of subjects alternated between several inhibi-
tors, unlike the results found in other studies
[19,20] where this was more frequent. Further-
more, we did not conﬁrm that the side effects of
the continued use of PDE5-i were rare, as
described by numerous studies, as around 55% of
men reported having noticed these effects, particu-
larly complaining of headaches, dyspepsia, and
nasal and ocular congestions. However, these were
reported in all cases with low intensity and do not
appear to be a reason to abandon treatment. In an
earlier study [13], only 12% of the men who
stopped the treatment had mentioned side effects
as the reason to abandon treatment.
Less than half of the male patients classiﬁed
their partners as “sexually active,” and a quarter
reported that their partner was “not important to
the resolution” of their ED problem. Equally
interesting is the ﬁnding that 19% of men
reported that their partner was unaware that
they were taking PDE5-i, which shows that the
relational dimension and the role of the partner
is not taken into account by a quarter of these
participants.
The main goal of this study was to identify the
factors that inﬂuence the adherence to treatment.
A qualitative analysis revealed four main groups of
factors that inﬂuence the use of PDE5-i. Psycho-
logical factors—the most frequently reported—are
related to self-conﬁdence, emotional states, and
fear (of drug side effects or regarding the cardio-
vascular safety). The second most reported by sub-
jects were medication-related factors. In some
occasions, participants do not take the drug
because they do not ﬁnd its efﬁcacy or because it is
expensive or because of the side effects. Relational
factors were the third most reported and are
related to the unavailability of partner (nonexis-
tence, disinterest, or lack of stimuli) and also
include those men who use the inhibitor only with
an extramarital sex partner. The last group of vari-
ables that inﬂuence the intake of the PDE5-i is the
circumstantial factors. These factors include situ-
ations where the intake of PDE5-i was mediated
by a punctual situation, e.g., to improve perfor-
mance or enhance pleasure. Moreover, other cir-
cumstantial variables prevent men from taking the
drug such as the difﬁculty in scheduling the medi-
cation intake or trying a natural product.
There are limitations to this study that must be
considered. The research was developed with a
sample of male participants attending a private
clinic for ED, which cannot be assumed to be
representative of all men suffering from ED due to
the fact that the clinic is highly specialized. Owing
to the private health care setting, the study popu-
lation is not fully representative of all social
and demographic variables. We also assume that
patients of higher socioeconomic status were over-
represented. Also, the frequency and patterns of
PDE5-i use were based on recall rather than on
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medication use log. Moreover, the instrument is
not a validated measure, and we did not address
the severity of ED.
Conclusion
This study highlighted the importance of tak-
ing psychological, relational, and circumstantial
factors into account in improving adherence, both
at the time of prescription and during the patient
post-prescription stage. Moreover, it is necessary
to assess issues of low conﬁdence and related fears,
as well as the involvement of respective patients’
partners in the treatment, where agreed possible.
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Appendix
1. Number of the clinical ﬁle:
2. What is your age?
3. Complete educational level:
4. Do you have a religion?
5. What is your marital status?
6. What is your relationship situation?
7. What is your sexual orientation?
8. Are you currently taking any pill for erectile dysfunction?
9. Which pills for erectile dysfunction are you currently taking?
10. What is the dosage?
11. What other pills did you take before?
12. Does your partner know you take those pills?
13. Do you consider your partner is involved in the resolution of
your problem?
14. Does your partner go with you and assist at the consultation?
15. Do you currently consider your partner to be sexually active?
16. For how long have you been taking these pills?
17. Do you use the pills in every intercourse?
18. How frequently do you use these pills?
19. How do you use the inhibitor?
20. Was the treatment with these pills according to your
expectations?
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21. Did you notice any side effect or something that did not please
you?
22. Besides this treatment, what other treatments have you done
for erectile dysfunction?
23. How frequently do you go to the follow-up consultation?
24. To what degree are you satisﬁed with your doctor?
25. Do you think this medication should be reimbursed?
26. Do you take antidepressants?
27. Do you take any other medication?
28. Are you a smoker? How many cigarettes do you smoke per
day?
29. Do you use other substances (drugs)?
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